Skip to main content

LCD L39387: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs

LCD L39387, Luteinizing Hormone-Releasing Hormone (LHRH) Analogs, is the Local Coverage Determination that Palmetto GBA applies to claims from 7 states (AL, GA, NC, SC, TN, VA, WV), effective 2024-10-10 and first in force 2023-02-19. The policy text runs 499 words, and its billing and coding article A59160 lists 180 ICD-10-CM codes that support medical necessity for 12 procedure codes. No other contractor publishes a policy with this title.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Palmetto GBA
States and territories
7
AL GA NC SC TN VA WV
Revision effective
2024-10-10
Original effective
2023-02-19
Policy text
499 words
Covered ICD-10 codes (articles)
180

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L39387
ContractContractorTypeStates
11201Palmetto GBAA and B and HHH MACSC
11301Palmetto GBAA and B and HHH MACVA
11401Palmetto GBAA and B and HHH MACWV
11501Palmetto GBAA and B and HHH MACNC
11202Palmetto GBAA and B and HHH MACSC
11302Palmetto GBAA and B and HHH MACVA
11402Palmetto GBAA and B and HHH MACWV
11502Palmetto GBAA and B and HHH MACNC
10111Palmetto GBAA and B MACAL
10211Palmetto GBAA and B MACGA
10311Palmetto GBAA and B MACTN
10112Palmetto GBAA and B MACAL
10212Palmetto GBAA and B MACGA
10312Palmetto GBAA and B MACTN

Billing and coding article A59160: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A59160 (Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A59160: Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (Billing and Coding, effective 2025-10-01)

Covered ICD-10-CM codes
180
7 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
12
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A59160
ICD-10-CMDescription (FY2027)
C08.0Malignant neoplasm of submandibular gland
C08.1Malignant neoplasm of sublingual gland
C08.9Malignant neoplasm of major salivary gland, unspecified
C48.0Malignant neoplasm of retroperitoneum
C48.1Malignant neoplasm of specified parts of peritoneum
C48.2Malignant neoplasm of peritoneum, unspecified
C48.8Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum
C50.011Malignant neoplasm of nipple and areola, right female breast
C50.012Malignant neoplasm of nipple and areola, left female breast
C50.019Malignant neoplasm of nipple and areola, unspecified female breast
C50.021Malignant neoplasm of nipple and areola, right male breast
C50.022Malignant neoplasm of nipple and areola, left male breast
C50.029Malignant neoplasm of nipple and areola, unspecified male breast
C50.111Malignant neoplasm of central portion of right female breast
C50.112Malignant neoplasm of central portion of left female breast
C50.119Malignant neoplasm of central portion of unspecified female breast
C50.121Malignant neoplasm of central portion of right male breast
C50.122Malignant neoplasm of central portion of left male breast
C50.129Malignant neoplasm of central portion of unspecified male breast
C50.211Malignant neoplasm of upper-inner quadrant of right female breast
C50.212Malignant neoplasm of upper-inner quadrant of left female breast
C50.219Malignant neoplasm of upper-inner quadrant of unspecified female breast
C50.221Malignant neoplasm of upper-inner quadrant of right male breast
C50.222Malignant neoplasm of upper-inner quadrant of left male breast

Procedure codes: 11981, 11982, 11983, 96402, J1950 (Injection, leuprolide acetate (for depot suspension), per 3.75 mg), J1952 (Leuprolide injectable, camcevi, 1 mg), J1954 (Injection, leuprolide acetate for depot suspension (lutrate depot), 7.5 mg), J3315 (Injection, triptorelin pamoate, 3.75 mg), J9202 (Goserelin acetate implant, per 3.6 mg), J9217 (Leuprolide acetate (for depot suspension), 7.5 mg), J9219 (Leuprolide acetate implant, 65 mg), J9225 (Histrelin implant (vantas), 50 mg).

Coverage indications, limitations and medical necessity

Luteinizing Hormone-Releasing Hormone (LHRH) Analogs are synthetic analogs of the naturally occurring gonadotropin releasing hormone (GnRH) with greater potency than the naturally occurring hormone, that when given inhibits pituitary gonadotropin secretion and suppresses testicular and ovarian steroidogenesis.

Leuprolide acetate (Lupron Depot ® ) , goserelin acetate (Zoladex ® ) , triptorelin pamoate (Trelstar ® ) , histrelin acetate (Vantas ® ) are synthetic LHRH agonists, analogs of the naturally occurring GnRH, and leuprolide mesylate (Camcevi ® ) . They will be covered for Food and Drug Administration (FDA) approved indications. The dose and frequency of administration should be consistent with the FDA approved labeling.

Covered Indications

Leuprolide Acetate is covered for endometriosis, uterine fibroids, advanced prostate cancer, head and neck cancer (salivary gland tumors), ovarian cancer/fallopian tube cancer/primary peritoneal cancer, premenopausal breast cancer, male breast cancer, central precocious puberty (CPP) and palliative treatment of advanced prostate cancer. 1 Leuprolide mesylate is covered for advanced prostate cancer. 12 The National Comprehensive Cancer Network ® (NCCN) Clinical Practice Guidelines in Oncology for Breast Cancer ® 14 , the NCCN Clinical Practice Guidelines in Oncology for Head and Neck Cancers ® 15 , the NCCN Clinical Practice Guidelines in Oncology for Ovarian Cancer ®16 , and the NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer ®17 are referenced for recommendations for coverage across each of these disease settings.

Goserelin implant is covered for locally confined prostate cancer in combination with flutamide; for stage T2b-T4 (stage B2-C) flutamide is recommended only with radiation in this disease setting. Goserelin implant is covered for advanced breast cancer in premenopausal and perimenopausal women, endometriosis, to thin the endometrial lining of the uterus prior to endometrial ablation for dysfunctional uterine bleeding, and palliative treatment of advanced prostate cancer. 2 The NCCN Clinical Practice Guidelines in Oncology for Breast Cancer ® is cited to nationally recognized guidelines to accommodate specific clinical scenarios. 14 The NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer ® is cited to nationally recognized guidelines to accommodate specific clinical scenarios for “advanced prostate cancer.” 17

Triptorelin pamoate is covered for palliative treatment of advanced prostate cancer. 3 The NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer ® is cited to nationally recognized guidelines to accommodate specific clinical scenarios for “advanced prostate cancer.” 17

Histrelin acetate implant is covered for CPP.

Note : The NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer ® is cited to nationally recognized guidelines to accommodate specific clinical scenarios for “advanced prostate cancer.” 17

Limitations

Services that are not reasonable and necessary cannot be covered by Medicare in the following:

• The dose and frequency of administration is not consistent with the FDA approved labeling. Doses and frequencies that exceed the FDA recommended dosage/frequency as per the prescribing information, are considered not reasonable and necessary and not covered by Medicare.

• It is contraindicated to administer these products if you have experienced any type of allergic reaction to these drugs or to any of its ingredients.

Summary of evidence (opening)

Lawrence, et al. (2020) conducted a systemic review to create the American Urological Association/American Society for Therapeutic Radiology and Oncology/Society of Urologic Oncology (AUA/ASTRO/SUO) Guideline to aid clinicians in the management of patients with advanced prostate cancer. Clinicians should offer ADT (androgen deprivation therapy) with either LHRH agonists or antagonists or surgical castration in patients with metastatic hormone sensitive prostate cancer (mHSPC) (strong recommendation; evidence level: grade B). The use of primary ADT for the management of mHSPC has been the standard of care (SOC) since its discovery by Huggins and colleagues in the 1940s. 5

Conn, et al. (1991) review article reports the use of GnRH agonist analogues therapy to induce biochemical castration. The suppression of the normal pituitary-gonadal function is sought because physiologic levels of secretion of gonadal steroids which exacerbate an underlying medical condition, such as endometriosis, uterine fibroids, or prostate cancer. 6

Guzick, et al. (2011) conducted a prospective, randomized, double-blind controlled trial to compare the efficacy of leuprolide and continuous oral contraceptives in the treatment of endometriosis associated pain. The major findings of this trial is that both treatment arms provided a significant reduction in pain from baseline and there was no significant difference in the extent of pain relief between the 2 treatment regimens. The strengths of this clinical trial include its study design (randomized, double-blind prospective, multicenter) and the choice of contemporary medical regimens currently in widespread clinical use in the United States. The greatest weakness of the study is its limited sample size, a direct result of significant challenges in subject recruitment. 7

Kendzierski, et al. (2018) assessed the efficacy of leuprolide depot in combination with an aromatase inhibitor delivered monthly compared to once every 3 months in premenopausal women with estrogen receptor (ER)-positive breast cancer in a single center retrospective study. The Suppression of Ovarian Function Trial (SOFT)/Tamoxifen and Exemestane Trial (TEXT) trials solidified GnRH agonists as a definitive option in adjuvant therapy for premenopausal women with ER-positive breast cancer. They concluded leuprolide acetate depot administered every 3 months is as efficacious and tolerable as a monthly injection in combination with an aromatase inhibitor for premenopausal patients with hormone receptor-positive breast cancer. The study’s retrospective design comes with inherent limitations. The patient population was small, and they describe a single institution experience not a larger randomized, multicenter trial of adjuvant hormone therapy in breast cancer patients. 9

The contractor cites 18 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2023-02-19
Current revision effective
2024-10-10
Last reviewed by the contractor
2024-09-04
MCD version
8

Other related documents: A59288 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Palmetto GBA hub lists every other active policy from the same contractor.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L39387 cover?

Luteinizing Hormone-Releasing Hormone (LHRH) Analogs are synthetic analogs of the naturally occurring gonadotropin releasing hormone (GnRH) with greater potency than the naturally occurring hormone, that when given inhibits pituitary gonadotropin secretion and suppresses testicular and ovarian steroidogenesis. The full 499-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L39387 apply to?

Palmetto GBA applies it to Medicare claims in 7 states: AL, GA, NC, SC, TN, VA, WV. It binds only that contractor; outside these jurisdictions the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L39387?

The companion billing and coding article A59160 lists 180 ICD-10-CM codes in 7 groups that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L39387?

A denial under LCD L39387 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A59160's 180 covered diagnosis codes, then file a redetermination with Palmetto GBA within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.